Recorded Presentation from the NCCN Pharmacy Updates: New Targets and Treatment Options for Acute Myeloid Leukemia
Recent advances have led to rational drug development as new therapeutically actionable molecular targets have emerged. It is important for clinicians to be aware of how to incorporate these novel treatment options into clinical practice in ways that achieve meaningful patient outcomes, as well as best practices for providing supportive care and patient education.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates on the Use of Immunotherapy and Targeted Therapy in Non-Small Cell Lung Cancer
Many new options exist for the treatment of advanced non-small cell lung cancer (NSCLC) in addition to traditional platinum-based chemotherapy. Pharmacists should be aware of the new data and recommendations for immunotherapies and targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies; therefore, pharmacists should educate patients about the possibility of adverse events and the need to report symptoms to their health care teams to avoid severe complications.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: The Role of the Pharmacist in Smoking Cessation and Education of Patients with Cancer
In order to improve smoking cessation efforts, health care providers need to understand options for smoking cessation therapy as well as the clinical data supporting these interventions. Pharmacists can play a critical role in patient education, therapy recommendations, and therapy management for smoking cessation.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Cervical Cancer, Version 1.2020
These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to first- and second-line systemic therapy recommendations for patients with recurrent or metastatic disease, and emerging evidence on a new histopathologic classification system for HPV-related endocervical adenocarcinoma.
Category
  • Cervical Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentations from the NCCN 2020 Congress Series: Breast Cancer
Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.
Category
Format
Credits
Recorded Presentation from the NCCN Pharmacy Updates: New Targets in Breast Cancer Therapy
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practices remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which we already have agents or are currently developing agents.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Staying up-to-date with the available treatment options is important for health care professionals to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profile is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
BCOP Test - Current Therapy Options for Graft-Versus-Host Disease
To be eligible to take the BCOP test, you must first complete all credit requirements for the educational activity. The test is available for an additional fee of $49. Each activity is this series is worth 1 hour of BCOP credit.
Category
Format
Credits
BCOP Test - New Targets and Treatment Options for Acute Myeloid Leukemia
To be eligible to take the BCOP test, you must first complete all credit requirements for the educational activity. The test is available for an additional fee of $49. Each activity is this series is worth 1 hour of BCOP credit.
Category
Format
Credits
BCOP Test - Updates on the Use of Immunotherapy and Targeted Therapy in Non-Small Cell Lung Cancer
To be eligible to take the BCOP test, you must first complete all credit requirements for the educational activity. The test is available for an additional fee of $49. Each activity is this series is worth 1 hour of BCOP credit.
Category
Format
Credits

Pages